CJC-1295 Dosage: Complete Guide to Protocols, Administration & Storage
CJC-1295 dosing is significantly simpler than daily peptide protocols because the DAC modification allows once-weekly administration. However, the administration process, reconstitution, injection technique, storage, and disposal, must be executed correctly to preserve peptide potency and ensure safety. This guide covers the complete practical picture from first injection to ongoing monitoring.
- CJC-1295 with DAC: standard dose is 1–2 mg once weekly via subcutaneous injection; the 8-day half-life makes weekly dosing sufficient for sustained GH elevation
- CJC-1295 without DAC (Modified GRF 1-29): 100–200 mcg per injection, administered 1–3 times daily often combined with ipamorelin in multi-peptide protocols
- Reconstituted CJC-1295 should be refrigerated immediately and used within 21–28 days; never freeze reconstituted peptide
- Injection timing for CJC-1295 without DAC: before bed or before exercise for best alignment with natural GH release; CJC-1295 with DAC can be injected any time of week
- Weekly injection site rotation is required to prevent localized reactions
- IGF-1 blood testing at baseline and at weeks 6–8 is the primary objective measure of treatment response
- All supplies including needles, alcohol wipes, sharps containers must be properly prepared before starting; safe disposal of needles is legally required
Dosing Protocols by Formulation
CJC-1295 with DAC
Standard dose: 1–2 mg once weekly via subcutaneous injection. Some protocols use 2 mg every 10 days, taking advantage of the extended half-life. Because DAC-modified CJC-1295 maintains sustained GH elevation throughout the week, timing within the day is less critical; maintaining a consistent weekly interval is most important.
CJC-1295 without DAC (Modified GRF 1-29)
Standard dose: 100–200 mcg per injection, administered 1–3 times daily. Most commonly used in combination with ipamorelin (a GHRP that amplifies GH release through a different receptor) at matching doses. This combination is typically injected before bed to align with the natural nocturnal GH peak, and/or before exercise.
Your physician determines which formulation and protocol is appropriate based on your goals, lifestyle, and dosing preference. For detailed protocols with dose-by-goal breakdown and how to compare with sermorelin dosing, see CJC-1295 & Sermorelin Dosing, Administration & Safety → and the CJC-1295 Dosage Calculator →.
Reconstitution
CJC-1295 arrives as lyophilized powder requiring reconstitution with bacteriostatic water. Standard syringe calculation uses a U-100 insulin syringe: divide desired dose in mg by concentration in mg/ml, then multiply by 100.
Critical reconstitution rules: bacteriostatic water only, not sterile water or saline. Never shake the vial — roll gently to dissolve. Solution should be clear and colorless; discard if cloudy. Refrigerate immediately and use within 21–28 days. Never freeze reconstituted CJC-1295.
For the complete GH response estimation tool and how to estimate your expected IGF-1 response at different doses, see the Growth Hormone Response Calculator →.
Injection Technique
CJC-1295 is administered subcutaneously, meaning it is injected into the fatty tissue beneath the skin. Preferred sites are the abdomen (2+ inches from navel), outer thigh, and outer upper arm. For the complete step-by-step injection guide with diagrams, see Subcutaneous Peptide Injection Technique Guide →.
Site rotation
Rotate injection sites every dose. For weekly CJC-1295 with DAC, you have a full week between injections at any given site, which is more than sufficient recovery. Never inject into the same spot consecutively.
Supplies, Storage, and Travel
For the complete supplies checklist, see CJC-1295 Supplies Checklist →. For storage and shipping guidance, see CJC-1295 Storage, Shipping & Handling Guidelines →. For travel-specific guidance, see Managing Peptide Therapy During Holiday & Travel →. For disposal, see Safe Disposal of Needles & Medical Waste →.
Tracking Your Progress
IGF-1 blood testing at baseline and at weeks 6–8 is the primary objective measure of CJC-1295 response. Rising IGF-1 within the normal physiologic range confirms the GH axis is responding to treatment. Your physician uses this alongside subjective reports of sleep, energy, body composition, and recovery to assess response and guide any protocol adjustment.
Tracking subjective factors such as sleep quality, workout performance, recovery time, energy levels, and body measurements provides valuable context between lab tests. For a comprehensive progress tracking framework with metrics and timelines, see Tracking CJC-1295 Progress: Metrics & Timelines →.
Frequently Asked Questions
How long until I need to inject again with CJC-1295 with DAC?
Once weekly is the standard protocol. Some patients use every 10 days, taking advantage of the 8-day half-life with a small buffer. Your physician determines the interval based on your IGF-1 response.
Can I miss a dose?
With the 8-day half-life of CJC-1295 with DAC, missing one week's injection will not produce an immediate drop-off; GH elevation persists for several days. Resume on your regular schedule the following week without doubling up.
Should I inject at a specific time of day?
For CJC-1295 with DAC, time of day is not critical; weekly consistency matters more. For CJC-1295 without DAC used in combination protocols, bedtime or pre-workout injection is preferred to align with natural GH release patterns.
What IGF-1 level should I be aiming for?
Your physician will establish a target range based on your age and baseline. Generally, the goal is to bring IGF-1 into the upper third of the normal range for your age group, not above the normal range.
Disclaimer
This content is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. CJC-1295 is available through licensed U.S. compounding pharmacies via physician prescription. Compounded medications are not FDA-reviewed for safety, quality, or efficacy. Consult a licensed healthcare provider before starting, changing, or stopping any treatment. Individual results vary.
